Having successfully closed a Series A financing for £28m, NodThera can now begin progressing molecules aimed at reducing chronic inflammation, known to be the root cause of a many diseases such as metabolic disorders, cancer and CNS diseases such as Alzheimer’s disease, the British biotech's chief science officer and acting CEO told Scrip.
Inflammasome's Time Has Come, Says Ex-GSK NodThera Chief After £28m Financing
CSO and acting CEO of UK-Based biotech outlines to Scrip plans to develop next generation NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation.
More from Strategy
• By
The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.
• By
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.